Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity.

O'Flaherty, E

Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity. [electronic resource] - Leukemia & lymphoma Oct 1997 - 343-9 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1042-8194

10.3109/10428199709059689 doi


Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Blood Preservation
Cell Count
Cell Survival--drug effects
Cells, Cultured
Cryopreservation
Cyclophosphamide--administration & dosage
Dose-Response Relationship, Drug
Epirubicin--administration & dosage
Erythroid Precursor Cells--drug effects
Granulocyte Colony-Stimulating Factor--administration & dosage
Hematopoietic Stem Cells--drug effects
Humans
Lymphoma, Non-Hodgkin--drug therapy
Phlebotomy